Dearborn Partners LLC Sells 4,731 Shares of Stryker Co. (NYSE:SYK)

Dearborn Partners LLC trimmed its position in Stryker Co. (NYSE:SYK - Free Report) by 4.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 106,067 shares of the medical technology company's stock after selling 4,731 shares during the period. Stryker makes up approximately 1.6% of Dearborn Partners LLC's holdings, making the stock its 24th biggest holding. Dearborn Partners LLC's holdings in Stryker were worth $38,318,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Centennial Bank AR increased its position in Stryker by 106.7% during the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company's stock valued at $32,000 after buying an additional 48 shares in the last quarter. Hara Capital LLC acquired a new stake in Stryker in the 3rd quarter worth approximately $42,000. HBW Advisory Services LLC purchased a new position in shares of Stryker in the third quarter worth $42,000. Grove Bank & Trust lifted its stake in shares of Stryker by 84.8% during the third quarter. Grove Bank & Trust now owns 122 shares of the medical technology company's stock worth $44,000 after buying an additional 56 shares during the period. Finally, DT Investment Partners LLC grew its holdings in shares of Stryker by 114.3% during the third quarter. DT Investment Partners LLC now owns 135 shares of the medical technology company's stock valued at $49,000 after buying an additional 72 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Trading Up 1.6 %

SYK traded up $6.14 during mid-day trading on Friday, hitting $389.42. 1,580,996 shares of the stock were exchanged, compared to its average volume of 1,260,860. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The company has a market cap of $148.45 billion, a PE ratio of 41.26, a PEG ratio of 2.93 and a beta of 0.91. The firm's fifty day moving average is $363.45 and its two-hundred day moving average is $346.97. Stryker Co. has a 1-year low of $282.35 and a 1-year high of $392.70.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.77 by $0.10. The firm had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. Stryker's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period last year, the business earned $2.46 EPS. Equities analysts forecast that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on SYK shares. Evercore ISI raised their price objective on Stryker from $380.00 to $384.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. lifted their price objective on shares of Stryker from $375.00 to $420.00 and gave the company an "overweight" rating in a research note on Wednesday, October 30th. StockNews.com upgraded shares of Stryker from a "hold" rating to a "buy" rating in a research note on Thursday. Needham & Company LLC boosted their target price on shares of Stryker from $393.00 to $409.00 and gave the company a "buy" rating in a research report on Wednesday, October 30th. Finally, Canaccord Genuity Group increased their price target on Stryker from $360.00 to $400.00 and gave the stock a "buy" rating in a research report on Wednesday, October 30th. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $393.65.

Insider Activity at Stryker

In related news, insider Viju Menon sold 600 shares of the firm's stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the transaction, the insider now owns 9,069 shares in the company, valued at approximately $3,219,495. This trade represents a 6.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP M Kathryn Fink sold 7,347 shares of Stryker stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the sale, the vice president now directly owns 10,042 shares in the company, valued at $3,685,213.16. This trade represents a 42.25 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 67,381 shares of company stock worth $24,825,275 over the last 90 days. Company insiders own 5.90% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.